glp-1 agonist therapy glp-1_analogs [TUSOM Five Unexpected New Uses for

Under commonly used obesity treatment criteria in Singapore, patients with a BMI of 30 or above may be considered for anti-obesity medication even without other medical conditions

doi: 10.1017/S0967199409990293 84 JahromiBNSadeghiSAlipourSParsanezhadMEAlamdarlooSM

Research Vial Dosing Phase III Equivalent Phase Day 1 onward Timing Every day Daily Dose 2 mg Notes No titration

The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver updated the terminology in 2023, renaming NAFLD as MASLD to better reflect the metabolic nature of the disease (Rinella et al., Hepatology 2023)